-

01:07:23 AM

VERU Stock News

VERU - Veru Inc

01/26/23 8:30 AM

Nasdaq : VERU

conferencesearnings

Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio webcast on Thursday, February 9,

RHEA-AI

neutral

01/10/23 8:30 AM

Nasdaq : VERU

management

Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease

RHEA-AI

neutral

12/05/22 6:30 AM

Nasdaq : VERU

earnings

Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results

U.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS European Medicines Agency’s (EMA) Emergency Task Force reviewing sabizabulin for emergency use in EU member states Sabizabulin also under review for potential emergency authorization by

RHEA-AI

neutral

11/28/22 8:30 AM

Nasdaq : VERU

conferencesearnings

Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio webcast on Monday, December 5, 2022,

RHEA-AI

neutral

11/09/22 8:55 PM

Nasdaq : VERU

covid-19

Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, announces the results of today’s meeting of the U.S. Food and Drug Administration’s (FDA)

RHEA-AI

negative

10/24/22 8:30 AM

Nasdaq : VERU

covid-19

Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced data from the late-breaker oral presentation of the Phase 3 trial of

RHEA-AI

neutral

10/13/22 8:30 AM

Nasdaq : VERU

conferencescovid-19

Veru to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that data from the Phase 3 trial of sabizabulin for hospitalized moderate to

RHEA-AI

neutral

10/04/22 4:30 PM

Nasdaq : VERU

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the granting of inducement awards to

RHEA-AI

neutral

09/21/22 8:30 AM

Nasdaq : VERU

conferences

Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will participate in

RHEA-AI

neutral

09/19/22 12:15 PM

Nasdaq : VERU

covid-19

Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

VERU Data

IndustryPharmaceutical Preparation Manufacturing
Websiteverupharma.com
CeoMitchell Steiner
Security nameVeru Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees233
Tags
- Consumer Non-Durables
- Household/Personal Care
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address48 NW 25th St Ste 102
StateFlorida
CityMiami
Zip33127-4442
CountryUnited States
Phone13125959123

About Veru Inc

Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules for the treatment of metastatic castration and androgen receptor resistant prostate cancer. VERU-100 is a novel, proprietary peptide formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. Zuclomiphene citrate is an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. The Veru breast cancer pipeline includes enobosarm for AR+/ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer. Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor agonist that targets and activates the androgen receptor in AR+/ER+/HER2- metastatic breast cancer without unwanted masculinizing side effects. VERU-111 is also being advanced into a Phase 3 trial for the treatment of hospitalized patients with COVID-19 who are at high risk for acute respiratory distress syndrome.